Baiji Shenzhou announced an exclusive licensing agreement for the new coronavirus and antibodies developed by Danshu Bio.

Introduction: Phase 1 and Phase 1/2 clinical trials are expected to be launched by early October this year, with healthy subjects and mild to moderate new coronary pneumonia patients respectively.
. On August 27, 2020, Baiji Shenzhou and Beijing Danshu Biopharmaceutical Co., Ltd. today announced that they have signed an exclusive licensing agreement to develop, produce and commercialize Danzia biosynthes in new coronavirus and antibodies, including DXP-593 and DXP-604, worldwide outside Greater China.
in preclinical studies, Dansor biology used high-flung single-cell sequencing techniques to screen several powerful and new coronavirus antibodies from blood samples recovered from neocyto pneumonia.
"Our goal is to find powerful new coronavirus and antibodies as soon as possible to develop a potential treatment that will benefit more patients than plasma therapy for patients in rehab," said Xie Xiaoliang, a professor at Peking University, director of the Center for High-Sharp Innovation in Future Genetic Diagnostics in Beijing and co-founder of Danshu Bio and chairman of the Scientific Advisory Board.
Xu Zhang, co-founder and CEO of Danshu Bio, said:
I believe that working with Baiji Shenzhou can effectively drive these major scientific research achievements to the next stage of development."
clinical development team of more than 1,300 employees in Baiji Shenzhou is strong and deep around the world dedicated to bringing innovative therapies to patients in need.
"Professor Xie Xiaoliang has made a major breakthrough in the study of new coronavirus antibodies, using high-flung single-cell sequencing technology to screen out antibodies that are expected to be in and out of the new coronavirus," commented Dr. Wang Li, Senior Vice President, Global Research, Clinical Operations and Biostatization and Asia-Pacific Clinical Development.
we are excited to launch clinical trials for this exciting research project and contribute to the development of new therapies to fight the new crown epidemic around the world.
A randomized, double-blind, placebo-controlled Phase 1 clinical trial is expected to start in Australia in September, with up to 30 healthy subjects in the group, while phase 1/2 clinical trials to be conducted in several countries will be launched by early October in patients with mild to moderate new coronary pneumonia.
information about the two clinical trials will be published above.
Under the terms of the agreement, Danshu Bio has authorized Baiji Shenzhou to have exclusive development, production and commercialization rights for its preclinical candidate drugs DXP-593, DXP-604, and other anti-new crown and antibodies outside Greater China.
plans to develop one or more drug candidates worldwide outside of Greater China, and Danshu Bio will retain the rights in Greater China.
Pharmaceuticals will receive a down payment and will be eligible for payment upon reaching the registration and commercialization milestones.
addition, Danshu Bio will be eligible for a double-digit sales tiered royalty for future products.
about DXP-593 and DXP-604DXP-593 and DXP-604 are two new coronavirus-infested antibodies screened from more than 60 new coronary pneumonia rehabilitation antigen B cells using high-flung single-cell transcription groups and VDJ sequencing techniques.
DXP-593 showed strong median activity in the fake and new coronavirus, with semi-inhibitory concentrations of 1.2 ng/ml and 15 ng/ml, respectively.
DXP-593 also has strong efficacy and preventive effects in rodent models infected with the new coronavirus.
the DXP-604 binding table is different from the DXP593, but also has high school and activity.
DXP-593 and DXP-604 are expected to be cocktail therapy options to avoid resistance caused by viral mutations.
.